Abstract 822: Target-specific nanoparticle-based strategy for improved therapeutic efficacy to treat pancreatic cancer
作者
Juan Luis Vivero-Escoto,Mubin Tarannum,Pinku Mukherjee
出处
期刊:Cancer Research [American Association for Cancer Research] 日期:2023-04-04卷期号:83 (7_Supplement): 822-822被引量:3
标识
DOI:10.1158/1538-7445.am2023-822
摘要
Abstract Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of the pancreatic cancer cases and is the fourth-leading cause of cancer-related mortality. Unfortunately, despite the tremendous scientific efforts, it is shocking to note that PDAC has the worst prognosis with 5-year survival rate of 10% which has not significantly improved from the past 40 years. The high mortality and awful prognosis of PDAC can be attributed to multifactorial reasons like its intrinsic and acquired resistant behavior, early micrometastatic dissemination, desmoplastic effect and heterogeneities in tumors, rendering the current treatments rather ineffective. Developing reliable methods for the effective treatment of PDAC will have a major impact on the clinical outcome for this deadly disease. Nanoparticle-based drug delivery using mesoporous silica nanoparticles (MSNs) can be a potential alternative for the treatment of PDAC owing to their outstanding properties such as high surface area, tunable pore diameters, external and internal surface, which make this platform suitable for high drug loading and functionalization. We have designed, synthesized and characterized a target-specific, stimuli-responsive MSN platform for the controlled delivery of cisplatin (cisPt) and gemcitabine (Gem) (TAB004-Gem-cisPt-MSNs) with an optimal drug ratio. Our results demonstrate that this delivery system effectively targets tumor associated MUC1 (tMUC1), increases therapeutic efficiency with reduced toxicity in both a syngeneic and a spontaneous mouse model that overexpressed tMUC1. Moreover, the same MSN platform has been used in a sequential treatment where MSNs containing a Sonic Hedgehog (SHh) inhibitor, cyclopamine (CyP), and the Gem-cisPt-MSNs as the main delivery system led to reduction in the tumor stroma along with an improvement in the treatment of PDAC. Taken together, our findings support the potential of drug delivery using MSN nanoparticles for stroma modulation and to prevent pancreatic cancer progression. Citation Format: Juan Luis Vivero-Escoto, Mubin Tarannum, Pinku Mukherjee. Target-specific nanoparticle-based strategy for improved therapeutic efficacy to treat pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 822.